keyword
MENU ▼
Read by QxMD icon Read
search

Polypill

keyword
https://www.readbyqxmd.com/read/28290999/polypills-an-essential-medicine-for-cardiovascular-disease
#1
EDITORIAL
The Lancet
No abstract text is available yet for this article.
March 11, 2017: Lancet
https://www.readbyqxmd.com/read/28290996/putting-polypills-into-practice-challenges-and-lessons-learned
#2
REVIEW
Ruth Webster, Jose M Castellano, Oyere K Onuma
Regulatory approvals for cardiovascular polypills are increasing rapidly across more than 30 countries. The evidence clearly shows polypills improve adherence and cardiovascular disease risk factors for patients with indications for use of polypill components-ie, those with established cardiovascular disease or at high risk. However, the implementation of polypills into clinical practice has many challenges. The clinical trials literature provides insights into the clinical impact of a polypill strategy, including cost-effectiveness, safety of use, substantial improvement in adherence, and better risk factor control than usual care...
March 11, 2017: Lancet
https://www.readbyqxmd.com/read/28290995/uses-of-polypills-for-cardiovascular-disease-and-evidence-to-date
#3
REVIEW
Mark D Huffman, Denis Xavier, Pablo Perel
Polypills have been approved in more than 30 countries, but worldwide experience with and availability of polypills remain limited, unlike fixed-dose combinations in other diseases such as HIV, tuberculosis, and malaria. In this Series review, we aim to propose a guide for the use of polypills in future research and clinical activities and to synthesise contemporary evidence supporting the use of polypills for prevention of atherosclerosis. Polypill uses can be categorised by population and indication, both of which influence the balance between benefits and risks...
March 11, 2017: Lancet
https://www.readbyqxmd.com/read/28286646/primary-prevention-of-cardiovascular-disease-a-review-of-contemporary-guidance-and-literature
#4
REVIEW
Jack Stewart, Gavin Manmathan, Peter Wilkinson
Cardiovascular disease is a significant and ever-growing problem in the United Kingdom, accounting for nearly one-third of all deaths and leading to significant morbidity. It is also of particular and pressing interest as developing countries experience a change in lifestyle which introduces novel risk factors for cardiovascular disease, leading to a boom in cardiovascular disease risk throughout the developing world. The burden of cardiovascular disease can be ameliorated by careful risk reduction and, as such, primary prevention is an important priority for all developers of health policy...
January 2017: JRSM Cardiovascular Disease
https://www.readbyqxmd.com/read/28263370/fixed-dose-combination-therapy-for-the-prevention-of-atherosclerotic-cardiovascular-diseases
#5
REVIEW
Ehete Bahiru, Angharad N de Cates, Matthew Rb Farr, Morag C Jarvis, Mohan Palla, Karen Rees, Shah Ebrahim, Mark D Huffman
BACKGROUND: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and disability worldwide, yet ASCVD risk factor control and secondary prevention rates remain low. A fixed-dose combination of blood pressure- and cholesterol-lowering and antiplatelet treatments into a single pill, or polypill, has been proposed as one strategy to reduce the global burden of ASCVD. OBJECTIVES: To determine the effect of fixed-dose combination therapy on all-cause mortality, fatal and non-fatal ASCVD events, and adverse events...
March 6, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28166827/the-polypill-approach-an-innovative-strategy-to-improve-cardiovascular-health-in-europe
#6
Valentín Fuster, Francesc Gambús, Aldo Patriciello, Margaretha Hamrin, Diederick E Grobbee
BACKGROUND: Cardiovascular disease (CVD) is a major cause of disability and premature death. Despite European guidelines advocating the use of medical therapies in CVD, many patients still do not achieve the guideline-recommended treatment, which highlights the need for change and innovations in this field. This requirement has been widely recognised by the national ministries of health, several European cardiology societies, and the European Parliament, who support the initiation of strategies to improve and promote cardiovascular health...
February 7, 2017: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/28077465/cost-effectiveness-of-the-polypill-versus-risk-assessment-for-prevention-of-cardiovascular-disease
#7
Bart S Ferket, M G Myriam Hunink, Mohammed Khanji, Isha Agarwal, Kirsten E Fleischmann, Steffen E Petersen
OBJECTIVE: There is an international trend towards recommending medication to prevent cardiovascular disease (CVD) in individuals at increasingly lower cardiovascular risk. We assessed the cost-effectiveness of a population approach with a polypill including a statin (simvastatin 20 mg) and three antihypertensive agents (amlodipine 2.5 mg, losartan 25 mg and hydrochlorothiazide 12.5 mg) and periodic risk assessment with different risk thresholds. METHODS: We developed a microsimulation model for lifetime predictions of CVD events, diabetes, and death in 259 146 asymptomatic UK Biobank participants aged 40-69 years...
April 2017: Heart: Official Journal of the British Cardiac Society
https://www.readbyqxmd.com/read/27993410/consensus-document-for-the-use-of-the-polypill-in-the-secondary-prevention-of-cardiovascular-disease
#8
José Ramón González-Juanatey, José María Mostaza, José María Lobos, Benjamín Abarca, José Luis Llisterri, Gonzalo Baron-Esquivias, Enrique Galve, Rosa María Lidón, Francisco Xavier Garcia-Moll, Pedro Luis Sánchez, Carmen Suárez, Jesús Millán, Vicente Pallares, José Juan Alemán, Isabel Egocheaga
Cardiovascular disease is a chronic disorder which is usually already at an advanced stage when the first symptoms develop. The fact that the initial clinical presentation can be lethal or highly incapacitating emphasizes the need for primary and secondary prevention. It is estimated that the ratio of patients with good adherence to secondary prevention of cardiovascular disease is low and also decreases gradually over time. The Polypill for secondary prevention of cardiovascular disease is the first fixed-dose combination therapy of salicylic acid, atorvastatin and ramipril approved in Spain...
February 9, 2017: Medicina Clínica
https://www.readbyqxmd.com/read/27972078/economic-evaluation-of-asa-100mg-simvastatin-40mg-and-ramipril-5-10mg-polypill-for-secondary-prevention-of-cardiovascular-events-in-mexico
#9
L Kaskens, A Gracia, M Rodriguez Mendoza, Y Escobar Juárez, G Mendoza Medrano, H Soto Molina
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27938845/polypill-can-its-potential-enhancement-of-efficacy-trigger-new-interest
#10
EDITORIAL
Jennifer Chao, Sameer Bansilal
No abstract text is available yet for this article.
December 2016: Global Heart
https://www.readbyqxmd.com/read/27892721/social-aspects-in-additive-manufacturing-of-pharmaceutical-products
#11
Johanna Lind, Sofia Kälvemark Sporrong, Susanne Kaae, Jukka Rantanen, Natalja Genina
Additive manufacturing (AM) techniques, such as drug printing, represent a new engineering approach that can implement the concept of personalized medicine via on-demand manufacturing of dosage forms with individually adjusted doses. Implementation of AM principles, such as pharmacoprinting, will challenge the entire drug distribution chain and affect the society at different levels. Areas covered: This work summarizes the concept of personalized medicine and gives an overview of possibilities for monitoring patients' health...
December 7, 2016: Expert Opinion on Drug Delivery
https://www.readbyqxmd.com/read/27844139/-cardiovascular-prevention-and-regular-physical-exercise-activity-and-training-as-the-true-polypill
#12
H Löllgen, N Bachl
Guidelines for cardiovascular prevention need to be regularly revised and updated. With respect to physical activity and exercise, many studies with practical relevance have been published in recent years. They are concerned with the evidence of physical activity for prevention of many diseases and the spectrum of indications for applying physical activity for prevention, therapy and rehabilitation. Training recommendations have been developed for the prevention of various diseases according to the FITT rule, which stands for frequency, intensity, time (of session) and type of sports followed by a progression in the amount of training...
December 2016: Herz
https://www.readbyqxmd.com/read/27818251/mesoporous-silica-nanoparticles-as-a-new-carrier-methodology-in-the-controlled-release-of-the-active-components-in-a-polypill
#13
Antonio L Doadrio, José M Sánchez-Montero, Juan C Doadrio, Antonio J Salinas, María Vallet-Regí
Polypill is a medication designed for preventing heart attacks through a combination of drugs. Current formulations contain blood pressure-lowering drugs and others, such statins or acetylsalicylic acid. These drugs exhibit different physical chemical features, and consequently different release kinetics. Therefore, the concentration in plasma of some of them after the release process can be out of the therapeutic range. This paper investigates a new methodology for the control dosage of a polypill recently reported containing hydrochlorothiazide, amlodipine, losartan and simvastatin in a 12...
January 15, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/27798363/the-polypill-an-effective-approach-to-increasing-adherence-and-reducing-cardiovascular-event-risk
#14
REVIEW
Peter Bramlage, Helen Sims, Joan Minguet, Carmen Ferrero
BACKGROUND: Despite a wide range of medications being available for the prevention of cardiovascular events such as stroke, myocardial infarction and mortality in both a primary and secondary setting, patient adherence to complex therapy regimens involving different drug classes remains low worldwide. Combining antiplatelet, antihypertensive, lipid-lowering and potentially further drugs into one 'polypill' has the potential to increase adherence, thereby reducing risk factors to a greater extent and for a longer duration...
October 19, 2016: European Journal of Preventive Cardiology
https://www.readbyqxmd.com/read/27754010/sp-03-1-polypill-strategy-to-improved-adherence
#15
Dorairaj Prabhakaran
Among individuals with established CVD, multiple medications (aspirin, blood pressure lowering drugs and statins) are required to manage CVD and it is well established that non adherence to prescribed treatments is substantial in the long term. Such discontinuation of CV-preventive medications and low adherence rates has been shown to affect the success of CVD prevention efforts. In low- and middle income countries only less than 20% patients receive recommended therapy for CVD prevention, but even in high-income countries treatment coverage in the community is only about 50% in those with heart disease and 35% in those with stroke...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27723064/the-food-and-drug-administration-fda-and-the-european-medicines-agency-ema-perspective-on-cardiovascular-polypill-a-multidimensional-concept
#16
LETTER
Mariusz Mogielnicki, Damian Swieczkowski, Witold Bachorski, Grzegorz Zuk, Natasza Gilis-Malinowska, Aleksander Zarzeka, Piotr Merks, Marcin Gruchala, Milosz Jaguszewski
No abstract text is available yet for this article.
2016: Cardiology Journal
https://www.readbyqxmd.com/read/27664074/an-integrated-general-practice-and-pharmacy-based-intervention-to-promote-the-use-of-appropriate-preventive-medications-among-individuals-at-high-cardiovascular-disease-risk-protocol-for-a-cluster-randomized-controlled-trial
#17
Adina Hayek, Rohina Joshi, Tim Usherwood, Ruth Webster, Baldeep Kaur, Bandana Saini, Carol Armour, Ines Krass, Tracey-Lea Laba, Christopher Reid, Louise Shiel, Charlotte Hespe, Fred Hersch, Stephen Jan, Serigne Lo, David Peiris, Anthony Rodgers, Anushka Patel
BACKGROUND: Cardiovascular diseases (CVD) are responsible for significant morbidity, premature mortality, and economic burden. Despite established evidence that supports the use of preventive medications among patients at high CVD risk, treatment gaps remain. Building on prior evidence and a theoretical framework, a complex intervention has been designed to address these gaps among high-risk, under-treated patients in the Australian primary care setting. This intervention comprises a general practice quality improvement tool incorporating clinical decision support and audit/feedback capabilities; availability of a range of CVD polypills (fixed-dose combinations of two blood pressure lowering agents, a statin ± aspirin) for prescription when appropriate; and access to a pharmacy-based program to support long-term medication adherence and lifestyle modification...
2016: Implementation Science: IS
https://www.readbyqxmd.com/read/27645895/polypills-for-the-prevention-of-cardiovascular-diseases
#18
REVIEW
Dhaval Kolte, Wilbert S Aronow, Maciej Banach
Cardiovascular diseases (CVD) remain the leading cause of death worldwide with an estimated 17.5 million deaths per year. Since its initial conception over a decade ago, the use of cardiovascular polypills has gained increasing momentum as a strategy to lower risk factor levels and prevent CVD. Several new data have emerged including the recent publication of the first outcomes trial using polypills. Areas covered: In this review, the authors summarize the current literature on the safety, efficacy, and cost-effectiveness of polypills for primary and secondary prevention of CVD, describe the current controversies in this field, and identify important areas for future research...
November 2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/27642921/sp-03-1-polypill-strategy-to-improved-adherence
#19
Dorairaj Prabhakaran
Among individuals with established CVD, multiple medications (aspirin, blood pressure lowering drugs and statins) are required to manage CVD and it is well established that non adherence to prescribed treatments is substantial in the long term. Such discontinuation of CV-preventive medications and low adherence rates has been shown to affect the success of CVD prevention efforts. In low- and middle income countries only less than 20% patients receive recommended therapy for CVD prevention, but even in high-income countries treatment coverage in the community is only about 50% in those with heart disease and 35% in those with stroke...
September 2016: Journal of Hypertension
https://www.readbyqxmd.com/read/27579548/cardiovascular-polypill-time-to-rethink
#20
Laxmi N Rao Bondugulapati
No abstract text is available yet for this article.
October 2016: Current Opinion in Lipidology
keyword
keyword
11650
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"